IGC Pharma Advances Alzheimer's Treatment Research

IGC Pharma, Inc. has expanded its clinical research program for IGC-AD1, an investigational Alzheimer's treatment. Building on Phase 2 interim results highlighting reductions in agitation and cognitive improvement, the company plans new trials to assess the therapy's potential as a disease-modifying option. This research will focus on cognitive function and biological markers like amyloid and tau levels.

The expanded trials are a crucial step in addressing Alzheimer's pathology. IGC-AD1 combines anti-neuroinflammatory properties with amyloid- and tau-targeting effects. Previous studies showed a 50% improvement in spatial memory and a 20% reduction in amyloid aggregation. The ongoing 146-patient Phase 2 trial is progressing, with over 1,000 doses administered without serious adverse events.

This initiative aims to forge strategic partnerships and deliver innovative therapies while generating substantial investor value. The upcoming Phase 2 trial reflects IGC Pharma's dedication to meeting the unmet needs of Alzheimer's patients and caregivers.